PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance

PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance

Abstract Background: Acquired resistance of chemotherapy, especially cisplatin, is a major challenge in lung cancer treatment. We conducted this study to examine whether a cyclin D kinase 4/6 (CDK4/6) inhibitor, PD 0332991, could reverse cisplatin resistance in human lung cancer cells. In addition,...

Full description

Bibliographic Details
Main Authors: Minghui Liu, Liyuan Cui, Xin Li, Chunqiu Xia, Yongwen Li, Rui Wang, Fan Ren, Hongyu Liu, Jun Chen
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Thoracic Cancer
Subjects:
chemotherapy
cisplatin
drug resistance
lung cancer
PD‐0332991
Online Access:https://doi.org/10.1111/1759-7714.13866

Internet

https://doi.org/10.1111/1759-7714.13866

Similar Items